AUROBINDO PHARMA Results Analysis-Q1FY27

Financial performance and key Operating Metrics (Consolidated) : Operating Revenue for Q1FY27 is Rs. 9,150 Crs., 16.3% growth YoY, Total Income is Rs. 9,415 Crs., 18.07% growth YoY, Gross Profit is Rs. 5,523 Crs., 19.32% growth YoY, EBITDA is Rs. 1,881 Crs., 17.32% growth YoY, EBITDA Margin is 20.56% improved by 18 basis points YoY, PBT Rs. 1,515 Crs., 25.55% growth YoY, PAT Rs. 1,032 Crs. 25.22% growth YoY. On QoQ basis Operating Revenue is up by 3.35%, Total Income is also up by 4.95%, Gross Profit is up by 1.83%, EBITDA is up by 4.45%, PBT is up by 17.39% and PAT is also up by 12.07%. Core U.S. generics performance and pipeline execution : U.S. revenue: +8.1% YoY to ₹3,770 cr ($399m), Lannett a “defining milestone,” strengthening the U.S. platform, adding complex/controlled substances exposure, and improving competitive positioning. Europe: sustained double-digit growth, margin uplift, and antibiotic seasonality : Revenue: €267m, +11% YoY in constant currency. Q1 as a “very strong start” and expects FY27 to close with double-digit growth. Growth Markets revenue: +38% YoY to ₹1,063 cr ($113m). it is broadly distributed-“no specific country, growing extraordinarily.” Expansion includes Indonesia and China; Canada is “doing well.” ARV formulations: Stable at $35m, “driven by stable volume.” China OSD site as a strategic investment: “production…doubled over past 12 months,” with increasing supply to Europe and the U.S. starting now. China OSD turning from EBITDA loss to positive on ramp and export flows. TheraNym described as de-risked via “contracted volumes” and staged capex, with explicit medium-term financial targets. Net capex $78m (mainly TheraNym Biologics). Despite $85m buyback and $247m Lannett acquisition payment, company reports net cash $42m, signaling continued financial flexibility